ProCE Banner Activity

CheckMate 649: Additional Analysis From the Phase III Trial of First-line Nivolumab + CT vs CT for Advanced Gastroesophageal Cancers

Slideset Download
Conference Coverage
In previously untreated patients with advanced gastroesophageal cancers, nivolumab plus chemotherapy significantly prolonged OS and PFS vs chemotherapy alone.

Released: June 10, 2021

Expiration: June 09, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme